Takeda’s Plasma Derived Therapies (PDT) Business Unit is a significant driver of innovation and growth for Takeda. Despite the pandemic, which has impacted the entire plasma industry, our PDT Business Unit continues to meet or exceed its goals. This is a testament to the team’s ongoing commitment to optimize our plasma business by investing in, expanding, and transforming significantly our end-to-end plasma operations and capabilities.
In a webcast on November 17, PDT’s leadership team shared updates on how the business has persevered and found opportunities to drive the plasma industry forward despite headwinds due to COVID-19. They highlighted progress against our ambitious strategy, and outlined recent examples of how Takeda is influencing the broader plasma ecosystem to realize the full value of plasma.
The webcast and presentation materials can be viewed here
Go deeper into our PDT business